Pesticides & Agrochemicals · Founded 1946 · www.piindustries.com · BSE 523642 · NSE PI INDUS.LTD · ISIN INE603J01030
No Notes Added Yet
Business
PI Industries Ltd. is a leading Indian agrochemical company with a strong presence in both domestic and international markets. The company operates through two primary business models:
Custom Synthesis & Manufacturing (CSM): This segment involves developing and manufacturing complex intermediates and active ingredients for global innovator agrochemical companies under long-term contracts. PI Industries leverages its R&D capabilities and manufacturing expertise to provide solutions for complex chemistries, operating primarily on a contract research and manufacturing basis (CRAMS). This business makes money through fees and product sales to global clients.
Domestic Agrochemicals (DAS): In this segment, PI Industries develops, manufactures, and markets a portfolio of differentiated insecticides, herbicides, fungicides, and plant growth regulators under its own brands in the Indian market. It generates revenue through direct sales of its branded products to farmers via an extensive distribution network.
Revenue Mix
PI Industries primarily operates in two distinct but complementary segments:
Custom Synthesis & Manufacturing (CSM/Exports): This segment is the larger contributor to the company's revenue, generally accounting for approximately 70-80% of the total revenue. It focuses on export markets, serving global agrochemical majors.
Domestic Agrochemicals (DAS): This segment caters to the Indian agricultural market and typically contributes approximately 20-30% of the total revenue.
Industry
PI Industries operates in the global agrochemical industry, which includes both the highly competitive generics market and the specialized innovator/patented molecules market.
Indian Agrochemical Market: This market is characterized by a large number of players, but PI Industries stands out due to its focus on differentiated, branded products and strong distribution. It is recognized as one of the prominent players in the premium segment within India.
Global Custom Synthesis & Manufacturing Market: This is a niche market requiring specialized R&D capabilities, advanced manufacturing infrastructure, and strong intellectual property protection. PI Industries is a globally recognized player in this space, known for its ability to handle complex chemistries and maintain long-term relationships with leading multinational agrochemical innovators. Its positioning is that of a reliable and technologically capable partner for global majors.
MOAT
PI Industries possesses several durable competitive advantages:
Strong R&D and Process Chemistry Expertise: Deep capabilities in complex chemistry and process innovation allow it to develop and manufacture advanced intermediates and active ingredients for global clients (CSM) and innovate its own product portfolio (DAS).
Long-term Client Relationships: In the CSM segment, it has established long-standing and trusted relationships with leading global agrochemical companies, which are difficult to replicate due to the high trust and technical complexity involved.
Integrated Manufacturing Capabilities: State-of-the-art manufacturing facilities with high compliance standards provide a cost advantage and ensure quality and reliability.
Extensive Domestic Distribution Network: A wide and deep reach across India ensures effective market penetration and brand building for its domestic agrochemical products.
Product Pipeline & Brand Equity: Continuous introduction of new and differentiated products in the domestic market, coupled with established brand recognition, provides a competitive edge.
Growth Drivers
Key factors that can drive growth for PI Industries over the next 3-5 years include:
Increasing Outsourcing in CSM: Global agrochemical companies are increasingly outsourcing R&D and manufacturing to specialized partners like PI Industries to optimize costs and focus on core competencies.
New Product Commercialization: Successful development and commercialization of new molecules from existing and new clients in the CSM segment, along with new branded product launches in the domestic market.
Global Food Security & Population Growth: Rising global population and the need for enhanced food production will continue to drive demand for crop protection chemicals.
Farmer Awareness & Adoption: Increasing awareness among Indian farmers regarding the benefits of advanced agrochemicals, supported by government initiatives to boost agricultural productivity.
Geographic Expansion: Potential for expanding its market reach in both CSM and domestic segments into new geographies.
Risks
Monsoon Dependence: The domestic agrochemical business is significantly impacted by the regularity and adequacy of monsoons in India, which can affect crop yields and farmer purchasing power.
Regulatory & Environmental Risks: Stringent and evolving environmental regulations globally and domestically, including potential bans or restrictions on certain active ingredients, could impact operations and product portfolios.
Raw Material Price Volatility: Fluctuations in the prices and availability of key raw materials and intermediates can affect manufacturing costs and margins.
R&D Success Rate: The success of new product development and commercialization for both CSM clients and proprietary products is crucial. R&D failures or delays can impact growth.
Intellectual Property Risks: While operating with strong IP protection, the risks associated with patent expirations for client molecules or potential infringement issues exist.
Currency Fluctuations: As a significant exporter, adverse movements in foreign exchange rates can impact export revenues and profitability.
Management & Ownership
PI Industries has a long-standing promoter group, the Aruns family, which holds a significant stake in the company. The management team is generally perceived as professional, experienced, and focused on long-term growth and innovation. The company's ownership structure includes a substantial promoter holding, along with significant institutional investor participation, indicating confidence from both the founding family and external investors.
Outlook
PI Industries holds a strong position in both the high-growth CSM segment and the resilient domestic agrochemical market. The bull case rests on the continued trend of global agrochemical majors outsourcing complex chemistries to partners like PI Industries, leading to sustained order book growth and new molecule development in CSM. Simultaneously, the domestic business is expected to benefit from increasing farmer awareness, government support for agriculture, and new product introductions, leveraging its strong distribution network. Operational efficiencies and a favorable product mix could further support margin expansion.
Conversely, the bear case highlights potential vulnerabilities such as erratic monsoons impacting domestic sales, heightened regulatory scrutiny leading to product bans or increased compliance costs, and volatility in raw material prices. Intense competition in both segments, combined with the inherent risks of R&D success and currency fluctuations, could also temper growth. Overall, PI Industries is positioned to benefit from structural trends in global agriculture and agrochemical outsourcing, but remains exposed to cyclical and regulatory risks inherent to the sector.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1898 | 1741 | 2069 | 2221 | 1901 | 1787 | 1901 | 1872 | 1376 | 1565 |
| Other Income | 56 | 58 | 73 | 122 | 76 | 73 | 86 | 83 | 67 | 76 |
| Total Income | 1954 | 1799 | 2142 | 2343 | 1977 | 1861 | 1986 | 1955 | 1442 | 1641 |
| Total Expenditure | 1344 | 1299 | 1486 | 1593 | 1389 | 1332 | 1381 | 1331 | 1073 | 1228 |
| Operating Profit | 610 | 500 | 656 | 750 | 588 | 529 | 605 | 624 | 369 | 413 |
| Interest | 7 | 11 | 8 | 9 | 8 | 8 | 4 | 3 | 6 | 4 |
| Depreciation | 78 | 80 | 83 | 80 | 99 | 90 | 97 | 98 | 105 | 107 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 105 | -2 |
| Profit Before Tax | 524 | 409 | 564 | 662 | 481 | 431 | 505 | 523 | 363 | 300 |
| Provision for Tax | 77 | 42 | 118 | 155 | 108 | 102 | 107 | 116 | 52 | 100 |
| Profit After Tax | 447 | 367 | 447 | 508 | 373 | 329 | 397 | 407 | 311 | 200 |
| Adjustments | 1 | 2 | 2 | 1 | 0 | 1 | 3 | 2 | 0 | 0 |
| Profit After Adjustments | 449 | 370 | 449 | 508 | 373 | 331 | 400 | 409 | 311 | 200 |
| Adjusted Earnings Per Share | 29.5 | 24.3 | 29.5 | 33.4 | 24.5 | 21.7 | 26.3 | 26.9 | 20.5 | 13.2 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1940 | 2096 | 2277 | 2277 | 2841 | 3367 | 4577 | 5300 | 6492 | 7666 | 7978 | 6714 |
| Other Income | 42 | 35 | 37 | 60 | 68 | 49 | 125 | 101 | 159 | 208 | 352 | 312 |
| Total Income | 1982 | 2132 | 2313 | 2337 | 2909 | 3415 | 4702 | 5401 | 6651 | 7874 | 8330 | 7024 |
| Total Expenditure | 1565 | 1663 | 1722 | 1782 | 2271 | 2647 | 3559 | 4154 | 4948 | 5638 | 5784 | 5013 |
| Operating Profit | 417 | 469 | 591 | 556 | 638 | 769 | 1143 | 1247 | 1703 | 2236 | 2547 | 2011 |
| Interest | 12 | 12 | 9 | 7 | 7 | 19 | 34 | 16 | 39 | 44 | 56 | 17 |
| Depreciation | 50 | 54 | 73 | 83 | 93 | 137 | 175 | 202 | 227 | 308 | 353 | 407 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 103 |
| Profit Before Tax | 355 | 403 | 510 | 466 | 538 | 614 | 939 | 1033 | 1444 | 1895 | 2142 | 1691 |
| Provision for Tax | 109 | 91 | 50 | 98 | 128 | 157 | 200 | 189 | 215 | 213 | 482 | 375 |
| Profit After Tax | 246 | 312 | 459 | 368 | 410 | 457 | 738 | 844 | 1230 | 1682 | 1660 | 1315 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Profit After Adjustments | 246 | 312 | 459 | 368 | 410 | 457 | 738 | 844 | 1230 | 1682 | 1660 | 1320 |
| Adjusted Earnings Per Share | 18 | 22.7 | 33.4 | 26.6 | 29.7 | 33.1 | 48.6 | 55.5 | 80.9 | 110.6 | 109.2 | 86.9 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 4% | 15% | 19% | 15% |
| Operating Profit CAGR | 14% | 27% | 27% | 20% |
| PAT CAGR | -1% | 25% | 29% | 21% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -28% | -8% | 1% | 15% |
| ROE Average | 18% | 19% | 18% | 22% |
| ROCE Average | 23% | 23% | 22% | 26% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 896 | 1171 | 1627 | 1925 | 2285 | 2619 | 5342 | 6120 | 7199 | 8731 | 10157 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 17 | 122 | 83 | 46 | 10 | 399 | 257 | 170 | 0 | 62 | 78 |
| Other Non-Current Liabilities | 61 | 64 | 20 | 15 | 34 | 106 | 694 | 703 | 825 | 1499 | 1488 |
| Total Current Liabilities | 948 | 972 | 1048 | 1808 | 1534 | 1917 | 1738 | 2004 | 1908 | 2185 | 2624 |
| Total Liabilities | 1922 | 2329 | 2779 | 3794 | 3863 | 5042 | 8032 | 8997 | 9931 | 12476 | 14347 |
| Fixed Assets | 533 | 874 | 945 | 998 | 1186 | 1858 | 2138 | 2453 | 2606 | 3528 | 4209 |
| Other Non-Current Assets | 179 | 118 | 119 | 140 | 264 | 344 | 920 | 925 | 937 | 1795 | 2290 |
| Total Current Assets | 1210 | 1336 | 1715 | 2656 | 2414 | 2840 | 4974 | 5620 | 6388 | 7153 | 7849 |
| Total Assets | 1922 | 2329 | 2779 | 3794 | 3863 | 5042 | 8032 | 8997 | 9931 | 12476 | 14347 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 32 | 18 | 34 | 85 | 117 | 61 | 125 | 110 | 351 | 873 | 887 |
| Cash Flow from Operating Activities | 184 | 367 | 339 | 319 | 391 | 698 | 725 | 529 | 1501 | 2036 | 1413 |
| Cash Flow from Investing Activities | -146 | -303 | -235 | -181 | -322 | -985 | -2430 | -110 | -496 | -1801 | -1424 |
| Cash Flow from Financing Activities | -53 | -48 | -53 | -106 | -125 | 350 | 1690 | -177 | -483 | -222 | -287 |
| Net Cash Inflow / Outflow | -15 | 16 | 50 | 33 | -56 | 63 | -15 | 241 | 522 | 14 | -298 |
| Closing Cash & Cash Equivalent | 17 | 34 | 84 | 117 | 61 | 125 | 110 | 351 | 873 | 887 | 592 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 18 | 22.72 | 33.39 | 26.64 | 29.72 | 33.09 | 48.57 | 55.51 | 80.89 | 110.63 | 109.22 |
| CEPS(Rs) | 21.65 | 26.68 | 38.7 | 32.65 | 36.46 | 42.99 | 60.07 | 68.79 | 95.79 | 130.9 | 132.41 |
| DPS(Rs) | 2.5 | 3.1 | 4 | 4 | 4 | 4 | 5 | 6 | 10 | 15 | 16 |
| Book NAV/Share(Rs) | 65.55 | 84.59 | 117.24 | 138.74 | 165.08 | 190.12 | 351.81 | 402.88 | 473.76 | 574.52 | 668.08 |
| Core EBITDA Margin(%) | 17.13 | 19.72 | 23.28 | 21.46 | 18.88 | 20.35 | 21.21 | 20.77 | 22.89 | 25.4 | 26.31 |
| EBIT Margin(%) | 16.78 | 18.86 | 21.75 | 20.48 | 18.06 | 17.89 | 20.26 | 19.01 | 21.99 | 24.27 | 26.36 |
| Pre Tax Margin(%) | 16.23 | 18.33 | 21.38 | 20.16 | 17.83 | 17.36 | 19.55 | 18.72 | 21.41 | 23.73 | 25.68 |
| PAT Margin (%) | 11.23 | 14.18 | 19.28 | 15.92 | 13.6 | 12.91 | 15.38 | 15.29 | 18.22 | 21.06 | 19.91 |
| Cash Profit Margin (%) | 13.5 | 16.65 | 22.34 | 19.52 | 16.68 | 16.78 | 19.02 | 18.95 | 21.58 | 24.92 | 24.13 |
| ROA(%) | 14.4 | 14.66 | 17.99 | 11.19 | 10.71 | 10.26 | 11.29 | 9.91 | 12.99 | 15.01 | 12.38 |
| ROE(%) | 30.99 | 30.32 | 33.14 | 20.84 | 19.57 | 18.63 | 18.52 | 14.71 | 18.45 | 21.11 | 17.58 |
| ROCE(%) | 40.23 | 35.53 | 33.77 | 25.18 | 25.1 | 23.13 | 22.09 | 17.4 | 21.84 | 24.14 | 22.99 |
| Receivable days | 53.3 | 64.81 | 62.9 | 75.14 | 71.9 | 67.51 | 51.32 | 52 | 44.38 | 38.9 | 51.11 |
| Inventory Days | 58.1 | 64.2 | 63.31 | 69.87 | 59.75 | 68.87 | 70.4 | 81.91 | 76.31 | 61.68 | 50 |
| Payable days | 110.71 | 113.4 | 102.59 | 102.49 | 103.8 | 109.05 | 98.44 | 107.41 | 90.52 | 99.19 | 118.95 |
| PER(x) | 33.81 | 24.97 | 25.07 | 33.33 | 34.7 | 35.35 | 46.42 | 50.82 | 37.42 | 34.97 | 31.35 |
| Price/Book(x) | 9.29 | 6.71 | 7.14 | 6.4 | 6.25 | 6.15 | 6.41 | 7 | 6.39 | 6.73 | 5.13 |
| Dividend Yield(%) | 0.41 | 0.55 | 0.48 | 0.45 | 0.39 | 0.34 | 0.22 | 0.21 | 0.33 | 0.39 | 0.47 |
| EV/Net Sales(x) | 4.33 | 3.76 | 5.05 | 5.36 | 5 | 4.91 | 7.24 | 7.88 | 6.74 | 7.34 | 6.23 |
| EV/Core EBITDA(x) | 20.12 | 16.8 | 19.46 | 21.96 | 22.24 | 21.49 | 28.98 | 33.47 | 25.7 | 25.15 | 19.5 |
| Net Sales Growth(%) | 21.61 | 8.04 | 8.61 | 0.01 | 24.76 | 18.5 | 35.96 | 15.79 | 22.5 | 18.08 | 4.07 |
| EBIT Growth(%) | 33.46 | 12.83 | 25.04 | -8.78 | 15.27 | 16.11 | 53.68 | 7.86 | 41.44 | 30.65 | 13.41 |
| PAT Growth(%) | 30.79 | 26.7 | 47.47 | -19.99 | 11.59 | 11.31 | 61.7 | 14.29 | 45.71 | 36.76 | -1.27 |
| EPS Growth(%) | 30.35 | 26.19 | 46.98 | -20.23 | 11.59 | 11.31 | 46.8 | 14.29 | 45.71 | 36.76 | -1.27 |
| Debt/Equity(x) | 0.13 | 0.13 | 0.07 | 0.04 | 0.02 | 0.2 | 0.06 | 0.04 | 0 | 0.01 | 0.01 |
| Current Ratio(x) | 1.28 | 1.38 | 1.64 | 1.47 | 1.57 | 1.48 | 2.86 | 2.8 | 3.35 | 3.27 | 2.99 |
| Quick Ratio(x) | 0.88 | 0.97 | 1.22 | 1.22 | 1.22 | 1.06 | 2.26 | 2.09 | 2.62 | 2.68 | 2.62 |
| Interest Cover(x) | 30.3 | 35.46 | 59.13 | 64.77 | 76.76 | 33.31 | 28.6 | 65.15 | 37.75 | 44.46 | 39.05 |
| Total Debt/Mcap(x) | 0.01 | 0.02 | 0.01 | 0.01 | 0 | 0.03 | 0.01 | 0.01 | 0 | 0 | 0 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 46.09 | 46.09 | 46.09 | 46.09 | 46.09 | 46.09 | 46.09 | 46.09 | 46.09 | 46.09 |
| FII | 20.41 | 20.26 | 18.76 | 19.02 | 18.46 | 18.05 | 16.97 | 16.42 | 15.97 | 15.87 |
| DII | 23.14 | 24.34 | 25.99 | 26.35 | 27.21 | 27.56 | 29.34 | 30.39 | 31.07 | 31.34 |
| Public | 10.37 | 9.32 | 9.16 | 8.55 | 8.25 | 8.3 | 7.6 | 7.1 | 6.87 | 6.71 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 6.99 | 6.99 | 6.99 | 6.99 | 6.99 | 6.99 | 6.99 | 6.99 | 6.99 | 6.99 |
| FII | 3.1 | 3.07 | 2.85 | 2.89 | 2.8 | 2.74 | 2.58 | 2.49 | 2.42 | 2.41 |
| DII | 3.51 | 3.69 | 3.94 | 4 | 4.13 | 4.18 | 4.45 | 4.61 | 4.71 | 4.75 |
| Public | 1.57 | 1.41 | 1.39 | 1.3 | 1.25 | 1.26 | 1.15 | 1.08 | 1.04 | 1.02 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15.17 | 15.17 | 15.17 | 15.17 | 15.17 | 15.17 | 15.17 | 15.17 | 15.17 | 15.17 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +4% | +15% | +19% | +15% |
| Operating Profit CAGR | +14% | +27% | +27% | +20% |
| PAT CAGR | -1% | +25% | +29% | +21% |
| Share Price CAGR | -28% | -8% | +1% | +15% |
| ROE Average | +18% | +19% | +18% | +22% |
| ROCE Average | +23% | +23% | +22% | +26% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 46.09 | 46.09 | 46.09 | 46.09 | 46.09 | 46.09 | 46.09 | 46.09 | 46.09 | 46.09 |
| FII | 20.41 | 20.26 | 18.76 | 19.02 | 18.46 | 18.05 | 16.97 | 16.42 | 15.97 | 15.87 |
| DII | 23.14 | 24.34 | 25.99 | 26.35 | 27.21 | 27.56 | 29.34 | 30.39 | 31.07 | 31.34 |
| Public | 53.91 | 53.91 | 53.91 | 53.91 | 53.91 | 53.91 | 53.91 | 53.91 | 53.91 | 53.91 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 6.99 | 6.99 | 6.99 | 6.99 | 6.99 | 6.99 | 6.99 | 6.99 | 6.99 | 6.99 |
| FII | 3.1 | 3.07 | 2.85 | 2.89 | 2.8 | 2.74 | 2.58 | 2.49 | 2.42 | 2.41 |
| DII | 3.51 | 3.69 | 3.94 | 4 | 4.13 | 4.18 | 4.45 | 4.61 | 4.71 | 4.75 |
| Public | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15.17 | 15.17 | 15.17 | 15.17 | 15.17 | 15.17 | 15.17 | 15.17 | 15.17 | 15.17 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.